A new AI system that creates simulated cancer genomes could reshape the tools used to analyze tumors, helping bring about more accurate cancer diagnosis and ultimately more effective treatments.
Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research from the University of Texas MD Anderson Cancer Center.
As we age, our cells replicate, and the DNA in these cells can acquire mistakes—or mutations—every time the sequence is copied. Most newly acquired mutations are harmless, but some can tip the balance toward cancer development later in life.
A new Northwestern Medicine study has revealed how a common inherited mutation disrupts red blood cell development and sparks inflammation that can lead to leukemia, according to findings published in Nature Communications.
Researchers develop a fast-acting, cell-permeable protein system to control CRISPR-Cas9, reducing off-target effects and advancing gene therapy.
By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in collaboration with scientists at the Paris Brain Institute and Örebro University, have identified why certain nerve cells are resistant to the disease and what happens in the sensitive nerve cells when they are affected.
A study led by Roswell Park Comprehensive Cancer Center helps explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers create a first-of-its-kind tool to guide treatment decisions for advanced kidney cancers.
Uppsala University Hospital-led investigators report that gene-edited donor islet cells survived 12 weeks inside a man with long-standing type 1 diabetes without any immunosuppressive medication.
Amyotrophic lateral sclerosis (ALS), known as Lou Gehrig’s disease, is an incurable neurological disorder affecting motor neurons—nerve cells in the brain and spinal cord that control voluntary muscle movement and breathing.
University of North Carolina Lineberger Comprehensive Cancer Center researchers have developed a “two-in-one” molecule that can simultaneously turn off two notoriously difficult-to-target cancer-related genes, KRAS and MYC, as well as directly deliver drugs to tumors that express these genes. This advance holds special promise for treating cancers that have been historically challenging to treat.